LGND has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
LGND has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Ligand Pharmaceuticals's Average Total Inventories for the quarter that ended in Dec. 2023 was $24.7 Mil. Ligand Pharmaceuticals's Revenue for the three months ended in Dec. 2023 was $28.1 Mil. Ligand Pharmaceuticals's Inventory-to-Revenue for the quarter that ended in Dec. 2023 was 0.88.
Ligand Pharmaceuticals's Inventory-to-Revenue for the quarter that ended in Dec. 2023 increased from Sep. 2023 (0.80) to Sep. 2023 (0.88)
An increase in Inventory-to-Revenue from one quarter to the next indicates that one of the following is happening:
1. investment in inventory is growing more rapidly than revenueDays Inventory indicates the number of days of goods in sales that a company has in the inventory. Ligand Pharmaceuticals's Days Inventory for the three months ended in Dec. 2023 was 1,372.39.
Inventory Turnover measures how fast the company turns over its inventory within a year. Ligand Pharmaceuticals's Inventory Turnover for the quarter that ended in Dec. 2023 was 0.07.
The historical data trend for Ligand Pharmaceuticals's Inventory-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ligand Pharmaceuticals Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Inventory-to-Revenue | Get a 7-Day Free Trial | 0.06 | 0.10 | 0.11 | 0.10 | 0.14 |
Ligand Pharmaceuticals Quarterly Data | ||||||||||||||||||||
Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
Inventory-to-Revenue | Get a 7-Day Free Trial | 0.35 | 0.31 | 0.78 | 0.80 | 0.88 |
For the Biotechnology subindustry, Ligand Pharmaceuticals's Inventory-to-Revenue, along with its competitors' market caps and Inventory-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Ligand Pharmaceuticals's Inventory-to-Revenue distribution charts can be found below:
* The bar in red indicates where Ligand Pharmaceuticals's Inventory-to-Revenue falls into.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Ligand Pharmaceuticals's Inventory-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as
Inventory-to-Revenue (A: Dec. 2023 ) | |||||||
= | Average Total Inventories | / | Revenue | ||||
= | ( (Total Inventories (A: Dec. 2022 ) | + | Total Inventories (A: Dec. 2023 )) | / | count ) | / | Revenue (A: Dec. 2023 ) |
= | ( (13.294 | + | 23.969) | / | 2 ) | / | 131.314 |
= | 18.6315 | / | 131.314 | ||||
= | 0.14 |
Ligand Pharmaceuticals's Inventory-to-Revenue for the quarter that ended in Dec. 2023 is calculated as
Inventory-to-Revenue (Q: Dec. 2023 ) | |||||||
= | Average Total Inventories | / | Revenue | ||||
= | ( (Total Inventories (Q: Sep. 2023 ) | + | Total Inventories (Q: Dec. 2023 )) | / | count ) | / | Revenue (Q: Dec. 2023 ) |
= | ( (25.392 | + | 23.969) | / | 2 ) | / | 28.101 |
= | 24.6805 | / | 28.101 | ||||
= | 0.88 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ligand Pharmaceuticals (NAS:LGND) Inventory-to-Revenue Explanation
An increase in Inventory-to-Revenue from one quarter to the next indicates that one of the following is happening:
1. investment in inventory is growing more rapidly than revenueLikewise, a decrease in the Inventory-to-Revenue from one quarter to next indicates that one of these is occurring:
1. investment in inventory is shrinking in relation to revenueMore Related Terms:
1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Ligand Pharmaceuticals's Days Inventory for the three months ended in Dec. 2023 is calculated as:
Days Inventory | = | Average Total Inventories (Q: Dec. 2023 ) | / | Cost of Goods Sold (Q: Dec. 2023 ) | * | Days in Period |
= | 24.6805 | / | 1.641 | * | 365 / 4 | |
= | 1,372.39 |
2. Inventory Turnover measures how fast the company turns over its inventory within a year.
Ligand Pharmaceuticals's Inventory Turnover for the quarter that ended in Dec. 2023 is calculated as
Inventory Turnover | = | Cost of Goods Sold (Q: Dec. 2023 ) | / | Average Total Inventories (Q: Dec. 2023 ) |
= | 1.641 | / | 24.6805 | |
= | 0.07 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of Ligand Pharmaceuticals's Inventory-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Martine Zimmermann | director | C/O LIGAND PHARMACEUTICALS INCORPORATED, 3911 SORRENTO VALLEY BOULEVARD SUITE 110, SAN DIEGO CA 92121 |
Todd C Davis | director | 11119 NORTH TORREY PINES ROAD, SUITE 200, LA JOLLA CA 92037 |
Andrew Reardon | officer: CHIEF LEGAL OFFICER & | C/O LIGAND PHARMACEUTICALS INCORPORATED, 3911 SORRENTO VALLEY BLVD, SUITE 110, SAN DIEGO CA 92121 |
Octavio Espinoza | officer: Chief Financial Officer | C/O LIGAND PHARMACEUTICALS INC, 3911 SORRENTO VALLEY BOULEVARD, STE 110, SAN DIEGO CA 92121 |
John W Kozarich | director | 10275 SCIENCE CENTER DR, SAN DIEGO CA 92121 |
Stephen L Sabba | director | DORSET MANAGEMENT CORP, 485 UNDERHILL BLVD SUITE 205, SYOSSET NY 11791 |
John L Higgins | officer: CEO & President | 11119 NORTH TORREY PINES ROAD, SUITE 200, LA JOLLA CA 92037 |
Jason Haas | director | C/O SYROS PHARMACEUTICALS, INC., 35 CAMBRIDGEPARK DRIVE, CAMBRIDGE MA 02140 |
Matthew W Foehr | officer: EVP and COO | 11119 NORTH TORREY PINES RD #200, LA JOLLA CA 92037 |
John L Lamattina | director | 81 WYMAN ST, POST OFFICE BOX 9046, WALTHAM MA 02454 |
Jennifer R. Cochran | director | C/O LIGAND PHARMACEUTICALS INC, 3911 SORRENTO VALLEY BOULEVARD, STE 100, SAN DIEGO CA 92121 |
Charles S Berkman | officer: Asso. Gen. Counsel, Secretary | 11085 NORTH TORREY PINES ROAD, SUITE 300, LA JOLLA CA 92037 |
Sunil Patel | director | 11085 NORTH TORREY PINES RD., SUITE 300, LA JOLLA CA 92037 |
Goldman Sachs Group Inc | 10 percent owner | 200 WEST STREET, NEW YORK NY 10282 |
Goldman Sachs & Co. Llc | 10 percent owner | 200 WEST STREET, NEW YORK NY 10282 |
From GuruFocus
By Marketwired • 11-06-2023
By Business Wire Business Wire • 12-13-2022
By Business Wire • 09-18-2023
By GuruFocus Research • 11-08-2023
By Business Wire Business Wire • 05-16-2023
By Business Wire • 09-26-2023
By Business Wire • 09-21-2023
By Business Wire • 01-05-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.